Related Experiment Video
Updated: Apr 15, 2026

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
Published on: December 9, 2014
Tango for treatment of motor and non-motor manifestations in Parkinson's disease: a randomized control study
Silvia Rios Romenets1, Julius Anang1, Seyed-Mohammad Fereshtehnejad2
1Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada.
Objective:
To determine effects of Argentine tango on motor and non-motor manifestations of Parkinson's disease.
Design:
Randomized control trial.
Participants:
Forty patients with idiopathic Parkinson's disease.
Setting:
Movement disorder clinic and dance studio.
Intervention:
Two randomized groups: group (N=18) with 24 partnered tango classes, and control self-directed exercise group (N=15).
Main Outcomes Measures:
The primary outcome was overall motor severity. Secondary outcomes included other motor measures, balance, cognition, fatigue, apathy, depression and quality of life.
Results:
On the primary intention-to-treat analysis there was no difference in motor severity between groups MDS-UPDRS-3 (1.6 vs.1.2-point reduction, p=0.85). Patient-rated clinical global impression of change did not differ (p=0.33), however examiner rating improved in favor of tango (p=0.02). Mini-BESTest improved in the tango group compared to controls (0.7±2.2 vs. -2.7±5.9, p=0.032). Among individual items, tango improved in both simple TUG time (-1.3±1.6s vs. 0.1±2.3, p=0.042) and TUG Dual Task score (0.4±0.9 vs. -0.2±0.4, p=0.012), with borderline improvement in walk with pivot turns (0.2±0.5 vs. -0.1±0.5, p=0.066). MoCa (0.4±1.6 vs. -0.6±1.5, p=0.080) and FSS (-3.6±10.5 vs. 2.5±6.2, p=0.057) showed a non-significant trend toward improvement in the tango group. Tango participants found the activity more enjoyable (p<0.001) and felt more "overall" treatment satisfaction (p<0.001). We found no significant differences in other outcomes or adverse events.
Conclusion:
Argentine tango can improve balance, and functional mobility, and may have modest benefits upon cognition and fatigue in Parkinson's disease. These findings must be confirmed in longer-term trials explicitly powered for cognition and fatigue.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Alzheimer's Disease: Treatment
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...

